跨领域IP合作

Search documents
名臣健康(002919):降本增效盘活资源,小程序游戏发展良好
HUAXI Securities· 2025-05-21 14:15
Investment Rating - The investment rating for the company is "Accumulate" [1] Core Views - The company reported a revenue of 1.38 billion yuan for 2024, a year-on-year decrease of 15.71%, and a net profit attributable to the parent company of 46.72 million yuan, down 33.60% year-on-year [2] - The company plans to distribute a cash dividend of 0.5 yuan per 10 shares (tax included) [2] - The gaming market in China reached a historical high in 2024, with actual sales revenue of 325.78 billion yuan, a year-on-year increase of 7.53% [5] - The company has been actively reducing costs and enhancing efficiency, with key products entering the public testing phase [4] Summary by Sections Financial Performance - In 2024, the company's daily chemical business gross margin was 40.03%, an increase of 1.80 percentage points year-on-year, while the gaming business gross margin was 57.91%, a decrease of 11.59 percentage points year-on-year [3] - The operating cash flow net amount was 165 million yuan, a year-on-year increase of 138.45% [3] - The company adjusted its revenue forecasts for 2025-2027 to 1.62 billion, 1.87 billion, and 2.09 billion yuan respectively [6] Business Development - The company has focused on developing mobile games and has successfully launched several mini-program games that have performed well in the market [4] - The company has a robust product pipeline and plans to launch products at the right time as they mature [4] Market Outlook - The self-developed overseas market achieved actual sales revenue of 18.557 billion yuan in 2024, a year-on-year increase of 13.39% [5] - The company is expected to benefit from the growth of the gaming market due to its strong product reserves and cost-reduction strategies [5]